Cargando…

Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer

BACKGROUND: In Her2-positive advanced breast cancer, the upfront use of trastuzumab is well established. Upon progression on first-line therapy, patients may be switched to lapatinib. Others however remain candidates for continued antibody treatment (treatment beyond progression). Here, we aimed to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bartsch, Rupert, De Vries, Catharina, Pluschnig, Ursula, Dubsky, Peter, Bago-Horvath, Zsuzsanna, Gampenrieder, Simon P, Rudas, Margaretha, Mader, Robert M, Rottenfusser, Andrea, Wiltschke, Christoph, Gnant, Michael, Zielinski, Christoph C, Steger, Guenther G
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2770076/ https://www.ncbi.nlm.nih.gov/pubmed/19835621 http://dx.doi.org/10.1186/1471-2407-9-367

Ejemplares similares

Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases
por: Bartsch, R, et al.
Publicado: (2012)

Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: An observational study
por: Bartsch, Rupert, et al.
Publicado: (2006)

Brain metastases free survival differs between breast cancer subtypes
por: Berghoff, A, et al.
Publicado: (2012)

Expression of thymidine phosphorylase in peripheral blood cells of breast cancer patients is not increased by paclitaxel
por: Bartsch, Rupert, et al.
Publicado: (2007)

Prognostic value of monitoring tumour markers CA 15-3 and CEA during fulvestrant treatment
por: Bartsch, Rupert, et al.
Publicado: (2006)

Trastuzumab in the management of early and advanced stage breast cancer
por: Bartsch, Rupert, et al.
Publicado: (2007)

Prognostic impact of breast cancer subtypes in elderly patients
por: Bergen, E. S., et al.
Publicado: (2016)

The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER(+), HER2(−) early breast cancer
por: Exner, R, et al.
Publicado: (2014)

Indocyanine Green Video Angiography Predicts Outcome of Extravasation Injuries
por: Haslik, Werner, et al.
Publicado: (2014)

Updated Austrian treatment algorithm in HER2+ metastatic breast cancer
por: Bartsch, Rupert, et al.
Publicado: (2022)

Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update
por: Rinnerthaler, Gabriel, et al.
Publicado: (2022)

Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response
por: Zhou, Qing, et al.
Publicado: (2022)

Tissue distribution of epirubicin after severe extravasation in humans
por: Nedomansky, Jakob, et al.
Publicado: (2021)

Extravasation emergencies: state-of-the-art management and progress in clinical research
por: Pluschnig, Ursula, et al.
Publicado: (2016)

Favourable outcome of patients with breast cancer brain metastases treated with dual HER2 blockade of trastuzumab and pertuzumab
por: Bergen, Elisabeth Sophie, et al.
Publicado: (2021)

Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients
por: Petricevic, Branka, et al.
Publicado: (2013)

Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial
por: Fiegl, Michael, et al.
Publicado: (2011)

Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients
por: Wimmer, Kerstin, et al.
Publicado: (2023)

Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial
por: Bartsch, Rupert, et al.
Publicado: (2022)

Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 status
por: Brodowicz, T, et al.
Publicado: (2001)

Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34
por: Bartsch, Rupert, et al.
Publicado: (2021)

The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial
por: Fitzal, F, et al.
Publicado: (2015)

PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2– disease: results from 1204 patients in the randomized ABCSG-8 trial
por: Fitzal, F, et al.
Publicado: (2021)

Prognostic value of HMGB1 in early breast cancer patients under neoadjuvant chemotherapy
por: Exner, Ruth, et al.
Publicado: (2016)

Factors influencing agreement of breast cancer luminal molecular subtype by Ki67 labeling index between core needle biopsy and surgical resection specimens
por: Tendl-Schulz, Kristina A., et al.
Publicado: (2020)

Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2− advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT
por: Steger, Guenther G., et al.
Publicado: (2020)

A clinical validation study of MammaPrint in hormone receptor-positive breast cancer from the Austrian Breast and Colorectal Cancer Study Group 8 (ABCSG-8) biomarker cohort
por: Dubsky, P., et al.
Publicado: (2020)

Decentral gene expression analysis for ER+/Her2− breast cancer: results of a proficiency testing program for the EndoPredict assay
por: Denkert, Carsten, et al.
Publicado: (2012)

Independent validation of stromal uPA in ABCSG-08: Level 1b evidence for the prognostic value of uPA immunohistochemistry
por: Singer, C.F., et al.
Publicado: (2022)

ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6
por: Filipits, M., et al.
Publicado: (2021)

Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series
por: Zagouri, F, et al.
Publicado: (2013)

PTEN expression as a predictor for the response to trastuzumab-based therapy in Her-2 overexpressing metastatic breast cancer
por: Gschwantler-Kaulich, Daphne, et al.
Publicado: (2017)

Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment
por: Hudelist, G, et al.
Publicado: (2003)

Recent developments and translational aspects in targeted therapy for metastatic breast cancer
por: Marhold, Maximilian, et al.
Publicado: (2016)

SABCS 2017 pathology: from bench to bedside
por: Bago-Horvath, Zsuzsanna
Publicado: (2018)

Inhibition of proliferation and induction of apoptosis in soft tissue sarcoma cells by interferon-α and retinoids
por: Brodowicz, T, et al.
Publicado: (1999)

Paclitaxel and carboplatin in patients with metastatic urothelial cancer: results of a phase II trial.
por: Zielinski, C. C., et al.
Publicado: (1998)

Development of the B cell cancer vaccine HER-vaxx for the treatment of her-2 expressing cancers
por: Ede, Nicholas J., et al.
Publicado: (2022)

Effect of Trastuzumab–HER2 Complex Formation on Stress-Induced Modifications in the CDRs of Trastuzumab
por: Spanov, Baubek, et al.
Publicado: (2022)

HER2/CEP17 Ratios and Clinical Outcome in HER2-Positive Early Breast Cancer Undergoing Trastuzumab-Containing Therapy
por: Stocker, Albina, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_qiq83dsn6plnpibrvh163257rf